Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

February 07, 2018

ViiV Healthcare Company et al v. Gilead Sciences, Inc.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. February 01, 2022

    Gilead Pays ViiV $1.25B Plus Royalties To End HIV Patent Suit

    Gilead has agreed to pay $1.25 billion plus royalties to GlaxoSmithKline venture ViiV Healthcare to settle claims Gilead infringed patents with its HIV drug, the companies announced Tuesday, a deal that comes less than a month after a trial in the high-profile case was delayed due to COVID-19.

3 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login